Scientists at Fred Hutch Cancer Center have reported an important advance in the effort to stop Epstein Barr virus (EBV), a ...

Most people have the Epstein-Barr (EBV) virus. Sometimes people are unaware of this virus in their body; it settles into ...

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of ...

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) Feb ...

Less than 14% of EBV-seronegative children received a kidney transplant from a seronegative deceased donor. In the United States, a majority of pediatric transplant recipients had unnecessary exposure ...

—A new study from Switzerland suggests that post-transplant lymphoproliferative disorders (PTLDs) may represent clonal expansions driven by exogenic immunosuppression, Epstein-Barr virus (EBV) ...

Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells. The Food and Drug Administration (FDA) has accepted for Priority Review the ...

Post-transplant lymphoproliferative disorders (PTLD) represent a heterogeneous group of lymphoid proliferations that emerge in the context of immunosuppression following solid organ or haematopoietic ...

Please provide your email address to receive an email when new articles are posted on . About half of patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease responded ...

Researchers are progressing towards a vaccine against Epstein-Barr virus (EBV), which affects 95% of the global population ...